Evidence map›Paper›PMID 38297397›Full record

ArticlePilot and feasibility studies2024

A randomized trial evaluating the utility of non-targeted biopsies for colorectal neoplasia detection in adults with inflammatory bowel disease: a pilot study protocol.

Sanjay K Murthy, Luba Marderfeld, Dean Fergusson, Tim Ramsay, Charles N Bernstein, Geoffrey C Nguyen, Vipul Jairath, Robert Riddell

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Pilot and feasibility studies, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04067778 (A Randomized, Parallel-Group, Non-Inferiority Trial Comparing Random AND Targeted Biopsies to Targeted Biopsies Alone for Neoplasia Screening in Adult Persons With Colonic Inflammatory Bowel Diseases), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04067778 nacompletednot on this map

A Randomized, Parallel-Group, Non-Inferiority Trial Comparing Random AND Targeted Biopsies to Targeted Biopsies Alone for Neoplasia Screening in Adult Persons With Colonic Inflammatory Bowel Diseases: A Pilot Study

TypeinterventionalSponsorOttawa Hospital Research InstituteRan2020 to 2022Enrolled600ConditionsInflammatory Bowel Diseases, Colonic Neoplasms, DysplasiaArmsIntervention Group, Control Group
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Sanjay K MurthyDepartment of Medicine, University of Ottawa, Ottawa, ON, Canada. smurthy@toh.ca.ORCID http://orcid.org/0000-0002-0128-7897
Luba MarderfeldThe Ottawa Hospital, IBD Centre, Ottawa, ON, Canada.
Dean FergussonClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Tim RamsayClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Charles N BernsteinDepartment of Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Geoffrey C NguyenMount Sinai Centre for Inflammatory Bowel Disease, University of Toronto, Toronto, ON, Canada.
Vipul JairathDepartment of Medicine, Western University, London, Canada.
Robert RiddellDepartment of Pathology, Mount Sinai Hospital, Toronto, ON, Canada.
University of Ottawa · CAMount Sinai Hospital · CAOttawa Hospital · CAUniversity of Manitoba · CAWestern University · CA

Funding

CIHR PJT 159607
6 · The paper itself

Abstract

backgroundPersons with inflammatory bowel diseases are at increased risk of developing colorectal cancer and require frequent colonoscopy surveillance. Guidelines recommend taking 30 to 40 non-targeted biopsies throughout the colorectum to detect "invisible" neoplasia in this setting, despite a lack of evidence supporting this practice. We sought to assess the utility of this practice through a randomized controlled trial. We first propose an internal pilot study to assess recruitment potential, protocol adherence and data capture to guide the full trial.

methodsWe have designed a multi-centre, parallel-group, non-inferiority randomized controlled trial to test the utility of non-targeted biopsies as an adjunct to colonoscopy surveillance for neoplasia detection in persons with inflammatory bowel disease involving the colorectum in routine clinical practice. Participants are randomized 1:1, stratified by study site, to either standard of care high-definition white-light colonoscopy with 32 to 40 non-targeted biopsies of non-neoplastic-appearing mucosa along with a sampling of abnormal-appearing mucosa (control group) or modified colonoscopy with targeted sampling alone (intervention group). The primary outcome for the full trial will be the proportion of persons with ≥ 1 neoplastic focus detected during colonoscopy. For the pilot phase, we will assess the feasibility of recruiting a minimum of 15% of the estimated sample size within 1 year, under identical conditions as the full trial, while maintaining ≥ 90-95% rate of protocol adherence and data capture. These participants will contribute data to the full trial. The trial is being conducted at 12 centres across Canada, with a total sample size of 1952 persons. DISCUSSIONS: The trial protocol has been approved by the ethics committees of all participating sites, and the pilot study has received funding through the Canadian Institutes of Health Research (PJT 159607). If feasibility metrics are met during the pilot phase, we will complete the full trial. The trial outcomes will contribute to update the practice guidelines in this area.

trial registrationClinicalTrials.gov, NCT04067778.

Indexed as

ColonoscopyColorectal cancerCrohn’s diseaseDysplasiaInflammatory bowel diseaseNeoplasiaRandom biopsyScreeningUlcerative colitis

Identifiers

PMID38297397
PMCPMC10832187
OpenAlexW4391445819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.